NASDAQ$AKYA
Akoya Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Akoya Biosciences reports first quarter 2025 financial results with a decrease in revenue and net loss, alongside an increase in gross margin.
Akoya Biosciences reported a revenue of $16.6 million for the first quarter of 2025, a decrease of 9.8% compared to the prior year. The company's net loss improved to -$15.652 million from -$23.484 million in the prior year period, and gross margin increased significantly to 59.3%.
- Revenue for Q1 2025 was $16.6 million, down 9.8% year-over-year.
- Gross margin improved to 59.3% in Q1 2025, up from 45.7% in the prior year period.
- Net loss for Q1 2025 was -$15.652 million, an improvement from -$23.484 million in the prior year.
- Operating expenses decreased by 22.3% to $23.3 million in Q1 2025.
Headline financials
Revenue & EPS history
Akoya · Revenue · Quarterly
$16.6M
Revenue by segment
Akoya · $18M total across 1 segment · Q3 2023
- Product revenue$18M+25.3%100.0%
Forward guidance
Akoya will not be hosting an earnings conference call or providing forward-looking guidance at this time due to the pending acquisition by Quanterix Corporation.
Tailwinds
- Continued focus on operational discipline and innovation.
- Successful increase in installed base despite macroeconomic uncertainty.
- Technology gaining momentum globally, with growing adoption in large-scale population studies.
- Expanding publication footprint across key research areas in high-impact journals.
- Confidence in value-creating opportunities from the integration with Quanterix.
Headwinds
- Broader macroeconomic uncertainty.
- NIH funding uncertainty.
- Pending acquisition by Quanterix Corporation means no earnings call.
- No forward-looking guidance provided at this time.
- Potential risks and uncertainties related to the proposed merger.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q1 2025
-3.7%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-17.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+13.7%
Q4 2021
Best reaction
-31.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | — | — | — | |
| Q1 2025 | +1.0% | +24.8% | +23.8% | |
| Q4 2025 | +3.8% | +9.2% | -30.7% | |
| Q3 2024 | -24.9% | -33.2% | -29.5% | |
| Q2 2024 | -9.5% | -0.9% | +5.5% | |
| Q1 2024 | -31.9% | -35.1% | -50.0% | |
| Q4 2023 | -15.4% | -17.1% | -28.1% | |
| Q3 2023 | +10.0% | +6.9% | +16.4% | |
| Q2 2023 | +0.9% | -6.5% | -23.9% | |
| Q1 2023 | -2.5% | -17.1% | -18.8% | |
| Q4 2022 | -7.3% | -17.2% | -36.6% | |
| Q3 2022 | -15.1% | — | — | |
| Q2 2022 | +5.0% | — | — | |
| Q1 2022 | -11.9% | — | — | |
| Q4 2021 | +13.7% | — | — | |
| Q3 2020 | +1.5% | — | — | |
| Q3 2021 | +0.2% | — | — | |
| Q2 2021 | -0.1% | — | — | |
| Q4 2020 | +9.5% | — | — | |
| Q1 2021 | +2.3% | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro